enGene (NASDAQ:ENGN) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of enGene (NASDAQ:ENGN) in a report issued on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $25.00 price objective on the stock. HC Wainwright also issued estimates for enGene’s Q1 2025 earnings at ($0.41) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.61) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.37 EPS.

ENGN has been the subject of a number of other reports. JMP Securities reissued a “market outperform” rating and set a $18.00 price target on shares of enGene in a research note on Friday, December 6th. Oppenheimer restated an “outperform” rating and issued a $30.00 price target on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 price target on shares of enGene in a research note on Wednesday, September 11th. Citizens Jmp upgraded enGene to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Raymond James assumed coverage on enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective on the stock. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $29.78.

enGene Stock Performance

NASDAQ:ENGN opened at $6.32 on Monday. The stock has a 50-day moving average price of $8.05 and a 200 day moving average price of $7.77. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene has a 12-month low of $4.42 and a 12-month high of $18.40. The stock has a market capitalization of $279.45 million, a P/E ratio of -10.90 and a beta of -0.78.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Equities research analysts forecast that enGene will post -1.52 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the stock in a transaction dated Friday, September 27th. The shares were purchased at an average price of $5.70 per share, with a total value of $57,000.00. Following the transaction, the chief executive officer now owns 10,000 shares in the company, valued at $57,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Growth Opportunities F. Forbion acquired 11,844 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average price of $6.55 per share, with a total value of $77,578.20. Following the completion of the transaction, the insider now owns 2,469,833 shares of the company’s stock, valued at $16,177,406.15. The trade was a 0.48 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 420,965 shares of company stock valued at $2,651,103. 13.70% of the stock is owned by insiders.

Institutional Trading of enGene

Hedge funds have recently made changes to their positions in the company. Logos Global Management LP grew its position in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after acquiring an additional 400,000 shares during the period. Franklin Resources Inc. lifted its stake in shares of enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares during the period. SR One Capital Management LP acquired a new stake in shares of enGene during the 2nd quarter worth about $4,715,000. Finally, Wolverine Asset Management LLC purchased a new stake in enGene in the 3rd quarter valued at about $37,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.